About Rocket Pharma
Rocket Pharma is a company based in New York (United States) founded in 2015. Rocket Pharma has completed 1 acquisition, including Renovacor. Rocket Pharma operates in a competitive market with competitors including Moderna, BridgeBio, Spark Therapeutics, Alnylam and ATAI, among others.
- Headquarter New York, United States
- Stage Public
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Rocket Pharmaceuticals, Inc.
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Latest Funding Round
$5 M (USD), Post-IPO
Dec 19, 2024
-
Investors
RTW Investments
& 4 more
-
Employee Count
Employee Count
- Investments & Acquisitions
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Rocket Pharma
Rocket Pharma is a publicly listed company on the NASDAQ with ticker symbol RCKT in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
People of Rocket Pharma
Unlock access to complete
Funding Insights of Rocket Pharma
- Total Funding Total Funding
- Total Rounds 6
- Last Round Post-IPO — $5.0M
-
First Round
First Round
(15 Jan 2016)
- Investors Count 5
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec, 2024 | Amount | Post-IPO - Rocket Pharma | Valuation |
investors |
|
| Aug, 2021 | Amount | Post-IPO - Rocket Pharma | Valuation |
investors |
|
| Nov, 2020 | Amount | Grant - Rocket Pharma | Valuation |
investors |
Investors in Rocket Pharma
Rocket Pharma has secured backing from 5 investors, including institutional and venture fund investors. Prominent investors backing the company include RTW Investments, CIRM and Tavistock Group.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Life Sciences focused VC firm investing in the US
|
Founded Year | Domain | Location | |
|
Tavistock Group is engaged in global diversified investments.
|
Founded Year | Domain | Location | |
|
Healthcare startups are funded by this corporate-backed venture capital entity.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Rocket Pharma
Rocket Pharma has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Renovacor.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
BAG3-related gene therapies for cardiovascular and CNS disorders are developed.
|
2013 |
Financial Statements - Rocket Pharma
Rocket Pharma Comparisons
Competitors of Rocket Pharma
Rocket Pharma operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, BridgeBio, Spark Therapeutics, Alnylam and ATAI, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| domain | founded_year | HQ Location |
Therapeutics for genetic diseases are developed through targeted interventions.
|
|
| domain | founded_year | HQ Location |
Gene therapies for rare diseases including retinal dystrophies are developed.
|
|
| domain | founded_year | HQ Location |
RNA interference-based therapeutics are developed for multiple disorders.
|
|
| domain | founded_year | HQ Location |
A biopharmaceutical company accelerating innovative mental health treatments.
|
|
| domain | founded_year | HQ Location |
An AI-enabled platform is developed for infectious disease treatment.
|
Latest news on Rocket Pharma
Frequently Asked Questions about Rocket Pharma
Rocket Pharma was founded in 2015 and raised its 1st funding round 1 year after it was founded.
Rocket Pharma is headquartered in New York, United States. It is registered at New York, New York, United States.
Rocket Pharma was founded in 2015 and is headquartered in New York, United States. Operations are centered in the biotechnology sector, where adeno-associated viral and lentiviral gene therapies are developed to address rare diseases. Specific therapies include RP-L102 for Fanconi anemia, RP-L201 for leukocyte adhesion deficiency, RP-L301 for pyruvate kinase deficiency, RP-L501 for Danon disease, and RP-A601 for PKP2-ACM, among others.
Rocket Pharma's top competitors include Moderna, Spark Therapeutics and BridgeBio.
Yes, Rocket Pharma is publicly traded on NASDAQ under the ticker symbol RCKT.
Rocket Pharma has made 1 acquisition, including Renovacor.
Rocket Pharma has 5 investors. Key investors include RTW Investments, CIRM, Tavistock Group, LifeSci Venture Partners, and Cormorant.
The ticker symbol of Rocket Pharma is RCKT on NASDAQ.